Sertraline in diabetic neuropathy: Preliminary results

Paul J. Goodnick, Isabel Jimenez, Adarsh Kumar

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = .05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.

Original languageEnglish (US)
Pages (from-to)255-257
Number of pages3
JournalAnnals of Clinical Psychiatry
Issue number4
StatePublished - 1997


  • Antidepressant
  • Blood levels
  • Diabetes mellitus
  • Neuropathy
  • Pain
  • Serotonin treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Sertraline in diabetic neuropathy: Preliminary results'. Together they form a unique fingerprint.

Cite this